Flapless Approach for the Treatment of Intrabony Defects
NCT ID: NCT05354037
Last Updated: 2022-04-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
40 participants
INTERVENTIONAL
2021-05-13
2023-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* to evaluate the comparative effectiveness of the proposed treatment evaluating patient-centered outcomes.
* to evaluate, after one year from the treatment, the comparative effectiveness evaluating clinical parameters: (I) Probing Depth (PD) measured from the gingival margin to the base of the pocket; (II) Recession (REC) measured as the distance between the CEJ and the gingival margin; (III) Presence of plaque in the site of intervention, measured dichotomously (Yes / No) (Plaque index (PI)); (IV) Presence of bleeding in the site of intervention, measured dichotomously (Yes / No) (Bleeding Index (BI)); (V) Full-mouth Bleeding Score (FMBS%); (VI) Full-mouth Plaque Score (FMPS%); (VII) the proportion of treated sites for each group that presented PD \<= 3 mm. ; (VIII) tooth retention
* to evaluate the comparative effectiveness evaluating radiographic parameters: (I) The distance between the Cemento-Enamel Junction (CEJ) and the bottom of the defect (CEJ-A) (II) the distance between the projection of the bone crest to the root surface and the bottom of the defect (representing the intrabony portion of the defect (III) C-A), and the distance between the bone crest and the root surface (representing the maximum width of the defect, C-B) were measured.
Control group: A buccal flap extending to the surfaces of the adjacent teeth will be elevated leading the interdental papilla in position following the M-MIST approach. After degranulation of the defect EMD will be applied following the standard procedure (after preparing root surface with Ethylenediamine tetraacetic acid (EDTA) 22% for two minutes). Non-resorbable 6/0 sutures will be used. The whole procedure will be performed using magnification devices (surgical loupes or surgical microscope). The operator will give postoperative instructions and information about medication.
Test group: The debridement of the pocket will be performed without the elevation of the flap, using ultrasonic tips, air polishing devices and curettes as standard procedure. After that, EMD will be applied and the same procedures as control group will be carried out. Non-resorbable 6/0 sutures will be used in the site of surgical intervention to close coronally the pocket.
At 7 days, suture removal, collection of questionnaires and clinical evaluation will be performed.
Follow-up visits will be carried out at 3, 6, 12, 18 and 24 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
EMD + M-MIST approach
Enamel matrix derivative application for treatment of intrabony defects
EMD application will be associated to M-MIST approach in control group and flapless approach in test group.
Group B
EMD with flapless approach
Enamel matrix derivative application for treatment of intrabony defects
EMD application will be associated to M-MIST approach in control group and flapless approach in test group.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Enamel matrix derivative application for treatment of intrabony defects
EMD application will be associated to M-MIST approach in control group and flapless approach in test group.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who are able to understand the requirements of the study and are willing and able to comply with its instructions and schedules
* Patients who had provided written informed consent to participate in the study prior to any study procedure
* Patients in general good health in the opinion of the principal investigator as determined by medical history and clinical examination (American Society of Anesthesiologists ASA 1 or ASA-2)
* Patients having one or more self-contained (3-wall or 2-3 walls) intrabony periodontal defect with an intrabony component of equal or more than 3 mm, as diagnosed by periapical radiographs and clinical evaluation.
Exclusion Criteria
* FMBS% \> 15%
* Treatment with anticoagulant drugs (International Normalized Ratio (INR) above 2,5)
* Treatment with intravenous bisphosphonates
* Treatment with anticonvulsants drugs
* untreated Periodontal disease and inability of the patient to maintain reasonable oral hygiene according to study requirements
* Patients with history of alcohol, narcotics or drug abuse
* Patients receiving radiotherapy, chemotherapy or any other immunosuppressive treatment or who have been administered radiotherapy in the last 5 years
* Patients through at any time received radiotherapy to the head and neck region will be excluded anyway
* Uncontrolled bleeding disorders such as: hemophilia, thrombocytopenia, granulocytopenia
* Degenerative diseases
* Osteoradionecrosis
* Renal failure
* Organ transplant recipients
* HIV positive (self-declaration)
* Malignant diseases
* Diseases that compromise the immune system
* Unbalanced diabetes (HbA1c above 7.2 assessed by self-declaration)
* Psychotic diseases
* Hypersensitivity or specific contraindications to one of the components of EMD
* Women who are pregnant (self-declaration); or lactating at the time of recruitment and of surgery
* Site where a history of failed periodontal regenerative procedure in the last two years
* Heavy Smokers (10 cigarettes and more per day).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stefano Corbella
Role: PRINCIPAL_INVESTIGATOR
University of Milan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Istituto Ortopedico Galeazzi
Milan, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Stefano Corbella, DDS, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FLPERIO
Identifier Type: -
Identifier Source: org_study_id